CER-001 Atherosclerosis Regression ACS Trial

NCT02484378 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Coronary Syndromes

Interventions

DRUG: CER-001
DRUG: Placebo

Sponsor

Cerenis Therapeutics, SA

Collaborators

[object Object]